Chronic Heart Failure and Lipidology
We recommend
Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule − inclisiran were presented at the Novartis company symposium.
Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk…
Practical Experiences Using ZULP in Cardiology
The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent…
Articles on this topic
How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?
Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolem…
Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Inclisiran − a new addition to the arsenal of dyslipidemia treatment
- The heart transplantation
- Practical Experiences Using ZULP in Cardiology
- How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?
- Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
- Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Journal on this topic
Related topic
Interesting links